IP Library › Granted Patent US 12,433,875
Granted Patent B2
US 12,433,875 · App. 17/780,611 · Granted Oct 7, 2025

(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification

Inventors: Lucio Claudio Rovati (Monza, IT); Gianfranco Caselli (Milan, IT); Tiziana Piepoli (Milan, IT)
Assignee: Rottapharm Biotech S.R.L.
A61K31/438A61P19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,875
App. No.
17/780,611
Granted
Oct 7, 2025
Kind
B2
Abstract

There is described a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof or the form A of its sodium salt for use in the prevention of heterotopic ossification. Preferably such a compound is effective in a specific dose range.

Claims (14)

1. A method for the prevention of heterotopic ossification in a subject affected by a disease selected from the group consisting of Myositis Ossificans, Post Surgical Heterotopic Ossification, Post-Injury Ossification, Osteosarcoma, at least one Spondyloarthropathy, at least one Seronegative arthropathy, Diffuse idiopathic skeletal hyperostosis, Para-articular Ossification, at least one Crystal-Induced Arthropathy, Osteoarthritis driven by degenerative processes, Hyperparathyroidism, Drug-Induced Ossification, and Ochronosis, Diffuse Idiopathic Skeletal Hyperstosis, Fibrodysplasia ossificans progressive, Synovial Endochromatosis and Progressive Osseous Heteroplasia, wherein said method comprises the step of administering to the subject a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is the sodium salt.

3. The method of claim 2 , wherein the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid is a polymorphic form of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoic acid characterized by a powder XRD spectrum with peaks at values of the angle 2θ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 (form A), said powder XRD spectrum recorded using a Cu K(α) radiation source, with wavelength values λ 1 =1.54051 Å and λ 2 =1.54430 Å.

4. The method according to claim 1 , wherein the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoic acid or its salt or the form A of its sodium salt is in a dose in the range from 1 to 30 mg/kg.

5. The method according claim 4 , wherein the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or its salt or the form A of its sodium salt is in a dose in the range from 8 to 20 mg/kg.

6. The method according claim 5 , wherein the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or its salt or the form A of its sodium salt is in a dose of about 10 mg/kg.

7. The method according to claim 1 , wherein the at least one Spondyloarthropathy is selected from the group consisting of Ankylosing spondylitis and Psoriatic arthritis.

8. The method according to claim 1 , wherein the Diffuse Idiopathic Skeletal Hyperstosis is caused by metabolic and/or degenerative processes.

9. A method for the prevention of heterotopic ossification in a subject affected by a disease selected from the group consisting of Myositis Ossificans, Post Surgical Heterotopic Ossification, Post-Injury Ossification, Osteosarcoma, at least one Spondyloarthropathy, at least one Seronegative arthropathy, Diffuse idiopathic skeletal hyperostosis, Para-articular Ossification, at least one Crystal-Induced Arthropathy, Osteoarthritis driven by degenerative processes, Hyperparathyroidism, Drug-Induced Ossification, and Ochronosis, Diffuse Idiopathic Skeletal Hyperstosis, Fibrodysplasia ossificans progressive, Synovial Endochromatosis and Progressive Osseous Heteroplasia, wherein said method comprises the step of administering to the subject a pharmaceutical composition comprising the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt or the form A of its sodium salt and at least one pharmaceutically acceptable excipient.

10. The method according to claim 9 , wherein the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoic acid or its salt or the form A of its sodium salt is in a dose in the range from 1 to 30 mg/kg.

11. The method according claim 10 , wherein the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or its salt or the form A of its sodium salt is in a dose in the range from 8 to 20 mg/kg.

12. The method according claim 11 , wherein the compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or its salt or the form A of its sodium salt is in a dose of about 10 mg/kg.

13. The method according to claim 9 , wherein the at least one Spondyloarthropathy is selected from the group consisting of Ankylosing spondylitis and Psoriatic arthritis.

14. The method according to claim 9 , wherein the Diffuse Idiopathic Skeletal Hyperstosis is caused by metabolic and/or degenerative processes.

Priority Claims (1)
EP 19212463 · Nov 29, 2019 · regional
Continuity (1)
Related Publication 20230028519A1 · Jan 26, 2023
References Cited (6)
WO 2020012305A1 · 2020 [cited by applicant]
Caselli, G. et al., “Chemical structure of CR6086”, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831858/pdf/13075_2018_Article_1537.pdf [retrieved on May 4, 2020], DOI: 10.1186/s13075-0… [cited by applicant]
Caselli, G. et al., “Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug”, Arthritis Res. & Ther., 20:39, https://doi.org… [cited by applicant]
Chiusaroli, R. et al., “THU0066 CR6086, a Selective Antagonist at the EP4 Prostanoid Receptor, Improves or Resolves Disease Features in a RAT Model of Rheumatoid Arthritis”, Retrieved from the Internet: URL:https://ard.… [cited by applicant]
Nakagawa, K. et al., “Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation”, Bone, 41(4), https://doi.org/10.1016/j.bone.2007.06.013, Sep. 14, 2007, 543-548. [cited by applicant]
Song, H-P. et al., “Phenotypic characterization of type II collagen-induced arthritis in Wistar rats”, Experimental and Therapeutic Medicine, 10(4), https://doi.org/10.3892/etm.2015.2667, Jul. 31, 2015, 1483-1488. [cited by applicant]